New combo therapy targets leukemia stem cells in blood cancer trial
NCT ID NCT06548230
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called nadunolimab combined with standard treatments (azacitidine, with or without venetoclax) in 40 adults with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to see if the combination is safe and to find the best dose. The study targets leukemia stem cells to improve treatment effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- New transplant cocktail aims to tame blood cancer without severe side effects
- Experimental drug tested for Post-Transplant blood cancers — but study halted early
- New drug cocktail shows promise for rare blood cancer
- New combo aims to cut infections in bone marrow cancer
- One donor, two transplants: could this end lifelong Anti-Rejection drugs?